Saturday 11 September
08:30

Saturday 11 September

Added to your list of favorites
Deleted from your list of favorites
A41
08:30 - 10:30

Plenary Session 7a

Moderators: Christelle BAUNEZ (Director of Research) (Marseille, France), Jean REGIS (PROFESSEUR) (MARSEILLE, France)
08:30 - 09:00 To sleep or not to sleep: that is the question for DBS procedures and Parkinson's disease. Hagai BERGMAN (Prof) (Jerusalem, Israel)
09:00 - 09:30 Immunity in the brain and radiosurgery. Bodo LIPPITZ (Co-Director) (Hamburg, Germany)
09:30 - 10:00 Deciphering the hodology of essential tremor. Constantin TULEASCA (Fellow, Neurooncology and Epilepsy) (Lausanne, Switzerland)
10:00 - 10:30 The future of Epilepsy Surgery. Hans CLUSMANN (Department of Neurosurgery) (Aachen, Germany)
Grand Amphithéâtre
10:30 COFFEE BREAK & VISIT OF POSTERS AND EXHIBITION
11:00

Saturday 11 September

Added to your list of favorites
Deleted from your list of favorites
A42
11:00 - 12:00

Plenary Session 7b

Moderators: Jocelyne BLOCH (Médecin Cadre) (Lausanne, Switzerland), Viktor JIRSA (Director INS) (Marseille, France), Joachim K. KRAUSS (Chairman and Director) (Hannover, Germany)
11:00 - 11:30 Controversies in movement disorders surgery: Should we offer DBS to dystonia patients regardless of etiology? Joachim K. KRAUSS (Chairman and Director) (Hannover, Germany)
11:30 - 11:45 #26205 - Long-term outcomes of ventral tegmental area deep brain stimulation for trigeminal autonomic cephalalgias.
Long-term outcomes of ventral tegmental area deep brain stimulation for trigeminal autonomic cephalalgias.

Objectives

                                                    

To present long-term outcomes of ventral tegmental area (VTA) deep brain stimulation (DBS) for medically refractory, chronic trigeminal autonomic cephalalgias 

 

Introduction

 

VTA DBS has been proven to be a safe and effective therapy for chronic cluster headache (CCH) and short-lasting unilateral neuralgiform headache attacks (SUNHA) in relatively small patient cohorts. The mechanism of action is not fully understood but is likely to involve the neuromodulation of the trigeminal parasympathetic reflex, which is triggered during attacks. To our knowledge, this is the largest series of patients that have undergone this procedure in a single centre.

 

Methods

 

Between 2009 and 2019, 71 patients (39 male and 32 female with an average age of 53 years [SD=13]) were treated with VTA DBS for chronic, medically refractory CCH (n=43) and SUNHA (n=28). Fifty-four patients underwent unilateral implantation (33 right), and 17 underwent bilateral implantations. Patients were assessed pre- and post-operatively by a specialist multidisciplinary team including headache neurologists, specialist nurses and functional neurosurgeons.

 

Results

 

The average follow-up was six years (SD=3.2). Response was set at 50% improvement in attack frequency. Forty-nine patients (69%) were responders with a mean improvement of 78% (SEM=2.7, SD=19.1, CL95%=5.5) and a median of 83%. In responders, headache severity on the verbal rating score (VRS) improved by a mean of 40% (SEM=5.2, SD=36.7, CL95%=10.5) and a median of 30% (3 points out of 10 in the CCH responders and 4.5 points in the SUNHA group). Attack duration in the responders improved by a mean of 37% (SEM=8, SD=56.1, CL95%=16.1) and a median of 50% from 120 to 45 minutes per attack in CCH and from 2 to 0.35 minutes in the SUNHA group. The headache load (HAL); a composite score encompassing frequency, severity, and duration of attacks improved by a mean of 73% (SEM=7.7, SD=52, CL95%=15) and a median of 89% in clinical responders.

 

Two thirds of patients (73% of responders and 48% of non-responders) had a stun effect during the postoperative period, which consisted in either complete symptom relief or in clinically significant reduction of the frequency, duration, or severity of the headaches. The mean length of the stun effect was 28 days (SEM=5.5, S=37.4, CL95%=11) and a median of 17 days. 

 

Four non-responders had the DBS system explanted, two of them secondary to infection and one due to post-surgical neuropathic pain around the head wound site. Two patients had the stimulation turned off due to absence of benefit. Four patients died due to unrelated conditions.

 

Conclusions

 

This open label study provides class IV evidence that VTA-DBS is a safe and effective long-term therapy for CCH and SUNHA.

 

Dr M Matharu and Mr H Akram contributed equally to this submission as co-senior authors


Olga PARRAS GRANERO (London, United Kingdom), Sanjay CHEEMA, Susie LAGRATA, Jonathan HYAM, Ludvic ZRINZO, Manjit MATHARU, Harith AKRAM
11:45 - 12:00 Connectivity Changes in the Salience Network after Cordotomy and Cingulotomy for Cancer Pain. Ido STRAUSS (Neurosurgeon) (Tel Aviv, Israel)
Grand Amphithéâtre
12:00

Saturday 11 September

Added to your list of favorites
Deleted from your list of favorites
A43
12:00 - 12:30

ESSFN Search grant and Awards 2021

Moderators: Jocelyne BLOCH (Médecin Cadre) (Lausanne, Switzerland), Antonio GONÇALVES FERREIRA (Head of the Stereotactic and Functional Division) (LISBON, Portugal), Jean REGIS (PROFESSEUR) (MARSEILLE, France)
12:00 - 12:30 3 Best oral communications and 3 best Posters. Niels Anthony VAN DER GAAG (neurosurgeon) (The Hague, The Netherlands), Kuan Hua KHO (Neurosurgeon) (Enschede, The Netherlands), Martin JAKOBS (Consultant) (Heidelberg, Germany)
12:00 - 12:30 Best Publication. Juan Antonio BARCIA (Neurosurgeon) (MADRID, Spain), Patric BLOMSTEDT (Neurosurgeon) (Umeå, Sweden), Lorand EROSS (Director of the institute) (Solymar, Hungary)
12:00 - 12:30 Best research awards. Jocelyne BLOCH (Médecin Cadre) (Lausanne, Switzerland), Stephan CHABARDÈS (head of the unit) (GRENOBLE, France), Bart NUTTIN (Professor) (Leuven, Belgium)
Grand Amphithéâtre